Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP)
Stock · NASDAQ · Health Care
$16.67as of 10/16/2026
Price chart
Active signals
FBIOP Signal Track Record
How signals performed across all stocks →What FBIOP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | +0.9% | 56% | October 5, 2026 |
| Bollinger Band Breakout | 22 | -2.3% | 36% | August 5, 2026 |
| Bollinger Band Breakdown | 20 | +4.1% | 65% | September 17, 2026 |
| 200-Day Moving Average TouchActive now | 17 | +2.1% | 65% | December 4, 2025 |
| Any 20-session window (baseline) | +0.7% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About FBIOP
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne;…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 78
- Website
- www.fortressbiotech.com/
Fundamentals
- 1-day range
- $16.39$16.97
- Market cap
- $662.39M
- P/E (trailing)
- 0.58
- P/E (forward)
- —
- EPS (trailing)
- $2.91
- Dividend yield
- —
- Beta
- 1.24
- Avg. volume
- 11.6K
- Ex-dividend date
- June 14, 2024
- Dividend pay date
- June 30, 2024
Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Competitors
Chosen by industry and closest market cap.
- FBIOPFortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock$16.67▼ 1.30%Market cap $662.39MP/E 0.58$1.88$4.53
- PHATPhathom Pharmaceuticals Inc. Common Stock$6.92▼ 7.73%Market cap $678.76MP/E —$6.52$18.31
- NGNENeurogene Inc. Common Stock$23.25▼ 2.92%Market cap $680.52MP/E —$15.93$43.66
- HELPCybin Inc. Common Stock$10.55▼ 4.52%Market cap $688.02MP/E —$5.3$20.88
- FTHFaeth Therapeutics Inc. Common Stock$18.8▼ 8.74%Market cap $632.57MP/E —$13.43$42.14
- EVOEvotec SE American Depositary Shares$1.38▼ 2.82%Market cap $693.72MP/E —$2.41$7.3
- IRWDIronwood Pharmaceuticals Inc. Class A Common Stock$3.5▼ 7.16%Market cap $701.25MP/E 4.68$1.41$5.78
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FBIOP Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock | $662.39M | 0.58 | $16.67 | ▼ 1.30% | $1.88$4.53 |
| PHAT Phathom Pharmaceuticals Inc. Common Stock | $678.76M | — | $6.92 | ▼ 7.73% | $6.52$18.31 |
| NGNE Neurogene Inc. Common Stock | $680.52M | — | $23.25 | ▼ 2.92% | $15.93$43.66 |
| HELP Cybin Inc. Common Stock | $688.02M | — | $10.55 | ▼ 4.52% | $5.3$20.88 |
| FTH Faeth Therapeutics Inc. Common Stock | $632.57M | — | $18.8 | ▼ 8.74% | $13.43$42.14 |
| EVO Evotec SE American Depositary Shares | $693.72M | — | $1.38 | ▼ 2.82% | $2.41$7.3 |
| IRWD Ironwood Pharmaceuticals Inc. Class A Common Stock | $701.25M | 4.68 | $3.5 | ▼ 7.16% | $1.41$5.78 |
P/E shows — for peers not currently carrying a live signal of their own.
See the full, filterable feed with live charts on the MarketWall dashboard.